Anthony Traboulsee

Anthony Traboulsee

Auto-generated profile, based on publicly available information

Anthony Traboulsee

Department of Medicine (Neurology), University of British Columbia, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in The Lancet Neurology
Verified
Journal Article
Closed access
ATAnthony Traboulsee
Anthony Traboulsee
BGBenjamin M Greenberg
Benjamin M Greenberg
JBJeffrey L Bennett
Jeffrey L Bennett
LSLech Szczechowski
Lech Szczechowski
EFEdward Fox
Edward Fox
BWBrian G Weinshenker
Brian G Weinshenker

1 November 2006 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
CLC Laule
C Laule
ELE Leung
E Leung
DLD Kb Li
D Kb Li
ATA L Traboulsee
A L Traboulsee
DPD W Paty
D W Paty
GMG Rw Moore
G Rw Moore
Various magnetic resonance (MR) techniques are used to study the pathological evolution of demyelinating diseases, such as multiple sclerosis (MS). However, few studies have validated MR derived measurements with histopathology. Here, we determine the correlation of myelin water imaging, an MR measure of myelin content, with quantitative histopathologic measures of myelin density. The multi-component T2 distribution of water was determined from 25 formalin-fixed MS brain samples using a multi-echo T2 relaxation MR experiment. The myelin water fraction (MWF), defined as T2 signal below 30 milliseconds divided by the total signal, was determined for various regions of interest and compared to Luxol fast blue (myelin stain) mean optical density (OD) for each sample. MWF had a strong correlation with myelin stain [mean (range) R2-/0.67 (0.45+ 0.92)], validating MWF as a measure of myelin density. This quantitative technique has many practical applications for the in vivo monitoring of demyelination and remyelination in a variety of disorders of myelin.

1 September 2016 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
GGGavin Giovannoni
Gavin Giovannoni
HBHelmut Butzkueven
Helmut Butzkueven
SDSuhayl Dhib-Jalbut
Suhayl Dhib-Jalbut
JHJeremy Hobart
Jeremy Hobart
GKGisela Kobelt
Gisela Kobelt
TVTimothy Vollmer
Timothy Vollmer
We present international consensus recommendations for improving diagnosis, management and treatment access in multiple sclerosis (MS). Our vision is that these will be used widely among those committed to creating a better future for people with MS and their families. Structured discussions and literature searches conducted in 2015 examined the personal and economic impact of MS, current practice in diagnosis, treatment and management, definitions of disease activity and barriers to accessing disease-modifying therapies (DMTs). Delays often occur before a person with symptoms suggestive of MS sees a neurologist. Campaigns to raise awareness of MS are needed, as are initiatives to improve access to MS healthcare professionals and services. We recommend a clear treatment goal: to maximize neurological reserve, cognitive function and physical function by reducing disease activity. Treatment should start early, with DMT and lifestyle measures. All parameters that predict relapses and disability progression should be included in the definition of disease activity and monitored regularly when practical. On suboptimal control of disease activity, switching to a DMT with a different mechanism of action should be considered. A shared decision-making process that embodies dialogue and considers all appropriate DMTs should be implemented. Monitoring data should be recorded formally in registries to generate real-world evidence. In many jurisdictions, access to DMTs is limited. To improve treatment access the relevant bodies should consider all costs to all parties when conducting economic evaluations and encourage the continuing investigation, development and use of cost-effective therapeutic strategies and alternative financing models. The consensus findings of an international author group recommend a therapeutic strategy based on proactive monitoring and shared decision-making in MS. Early diagnosis and improved treatment access are also key components.

6 October 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
ABAmit Bar-Or
Amit Bar-Or
JCJonathan C. Calkwood
Jonathan C. Calkwood
CCCathy Chognot
Cathy Chognot
JEJoanna Evershed
Joanna Evershed
EFEdward J. Fox
Edward J. Fox
ATAnthony Traboulsee
Anthony Traboulsee
Objective The phase IIIb A Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Participants With Relapsing Forms of Multiple Sclerosis (VELOCE) study (NCT02545868) assessed responses to selected vaccines in ocrelizumab (OCR)-treated patients with relapsing multiple sclerosis. Methods Patients were randomized 2:1 into the OCR group (n = 68; OCR 600 mg) or control group (n = 34; interferon beta or no disease-modifying therapy). All received tetanus toxoid (TT)-containing vaccine, Pneumovax (23-valent pneumococcal polysaccharide vaccine [23-PPV]), and keyhole limpet hemocyanin (KLH). The OCR group was subdivided into OCR1 (n = 33) and OCR2 (n = 35) at randomization. The OCR1 group received Prevnar (13-valent conjugate pneumococcal vaccine) 4 weeks after 23-PPV; the OCR2 and control groups received influenza vaccine. Vaccinations started 12 weeks after OCR initiation (OCR group) or on day 1 (control group). Results Positive response rate to TT vaccine at 8 weeks was 23.9% in the OCR vs 54.5% in the control group. Positive response rate to ≥5 serotypes in 23-PPV at 4 weeks was 71.6% in the OCR and 100% in the control group. Prevnar did not enhance response to pneumococcal serotypes in common with Pneumovax. Humoral response to KLH was decreased in the OCR vs control group. Seroprotection rates at 4 weeks against 5 influenza strains ranged from 55.6% to 80.0% in the OCR2 group and 75.0% to 97.0% in the control group. Conclusion Peripherally B-cell–depleted OCR recipients mounted attenuated humoral responses to clinically relevant vaccines and the neoantigen KLH, suggesting that use of standard nonlive vaccines while on OCR treatment remains a consideration. For seasonal influenza vaccines, it is recommended to vaccinate patients on OCR because a potentially protective humoral response, even if attenuated, can be expected. Classification of evidence This study provides Class II evidence confirming that the humoral response to nonlive vaccines in patients with relapsing multiple sclerosis after OCR treatment is attenuated compared with untreated or interferon beta–treated patients, but they can still be expected to be protective. Clinicaltrials.gov identifier NCT02545868.

12 November 2015 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ATA. Traboulsee
A. Traboulsee
JSJ.H. Simon
J.H. Simon
LSL. Stone
L. Stone
EFE. Fisher
E. Fisher
DJD.E. Jones
D.E. Jones
DLD. Li
D. Li
SUMMARY: An international group of neurologists and radiologists developed revised guidelines for standardized brain and spinal cord MR imaging for the diagnosis and follow-up of MS. A brain MR imaging with gadolinium is recommended for the diagnosis of MS. A spinal cord MR imaging is recommended if the brain MR imaging is nondiagnostic or if the presenting symptoms are at the level of the spinal cord. A follow-up brain MR imaging with gadolinium is recommended to demonstrate dissemination in time and ongoing clinically silent disease activity while on treatment, to evaluate unexpected clinical worsening, to re-assess the original diagnosis, and as a new baseline before starting or modifying therapy. A routine brain MR imaging should be considered every 6 months to 2 years for all patients with relapsing MS. The brain MR imaging protocol includes 3D T1-weighted, 3D T2-FLAIR, 3D T2-weighted, post-single-dose gadolinium-enhanced T1-weighted sequences, and a DWI sequence. The progressive multifocal leukoencephalopathy surveillance protocol includes FLAIR and DWI sequences only. The spinal cord MR imaging protocol includes sagittal T1-weighted and proton attenuation, STIR or phase-sensitive inversion recovery, axial T2- or T2*-weighted imaging through suspicious lesions, and, in some cases, postcontrast gadolinium-enhanced T1-weighted imaging. The clinical question being addressed should be provided in the requisition for the MR imaging. The radiology report should be descriptive, with results referenced to previous studies. MR imaging studies should be permanently retained and available. The current revision incorporates new clinical information and imaging techniques that have become more available.

1 October 2012 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
DKDorlan J. Kimbrough
Dorlan J. Kimbrough
KFKazuo Fujihara
Kazuo Fujihara
AJAnu Jacob
Anu Jacob
MLMarco A. Lana-Peixoto
Marco A. Lana-Peixoto
MLMaria Isabel Leite
Maria Isabel Leite
DWDean M. Wingerchuk
Dean M. Wingerchuk